The COVID-19 vaccine being developed by Oxford University and AstraZeneca has achieved 70% efficacy in the first Phase III interim analysis – with an "intriguing" signal which suggests a lower first dose could boost this result to 90%.
The results are the third positive readout from a COVID-19 vaccine trial in as many weeks, following the 90% plus...






